The new FDA approved short-acting insulin drug can be used to treat T1 and T2 diabetes.
The FDA has approved two new treatments, Tresiba and Ryzodeg, for both type 1 and type 2 diabetes.
The drug is approved for patients who are unable to control their LDL cholesterol with current treatment options.
The FDA approval of a pediatric indication for Oxycontin creates a safer situation for terminally ill children.
The FDA has approved a pediatric indication for OxyContin in patients as young as 11 years.
An intragastric balloon receives approval as a non-surgical weight loss procedure for patients with mild-to-moderate obesity.
Two new therapies to treat irritable bowel syndrome, eluxadoline and rifaximin, have been approved by the FDA.
Spray-dried fibrin sealant promotes clotting when other methods are "ineffective or impractical."
The FDA has granted expanded the use of Eylea injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).
New drug targets cell walls of the fungi and is available in oral and intravenous formulations.
The FDA has approved Cohera Medical's TissuGlu Surgical Adhesive, the first tissue adhesive for internal use.
The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.
The FDA has approved esomeprazole magnesium delayed-release capsules, the first generic version of AstraZeneca's Nexium.
Perindopril arginine and amlodipine besylate may be used as initial therapy if a patient is likely to need multiple drugs to achieve their blood pressure goals.
Secukinumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Savaysa (edoxaban) is indicated to treat deep vein thrombosis and pulmonary embolism and prevent stroke.
The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management.
Patients given paramivir had flu symptoms ease 21 hours sooner compared with patients left untreated.
The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B
Results showed that patients who took Contrave had an average weight loss of 4.1% more compared with patients who were assigned placebo.
The FDA has approved three drugs to treat ABSSI in 2014.
Pivotal trials showed that empagliflozin improved hemoglobin A1c levels compared with placebo.
The medication is designed to deter abuse of the drug by snorting or injection.
Afrezza can be used for the improvement of glycemic control in adult patients with diabetes mellitus.
The antibiotic is designed to treat infections including MRSA.
Brodalumab binds to the IL-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.
The FDA has approved vedolizumab for patients with inadequate response to conventional therapies.
Diarrhea, nausea and headache were the most common side effects observed in patients treated with apremilast.
Inappropriate use in children under 15 years old and patients seeking relief for asthma cited as top concerns.
Merck's Grastek becomes the second sublingual treatment for grass pollen-induced allergic rhinitis with or without conjunctivitis.